Tie-2

MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.

Pexmetinib is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase.

Tie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 μM.

XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.

AMG-Tie2-1 is a highly potent, non-selective inhibitor of Tie-2 (IC50 <1 nM).

Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.

Sodium succinate dibasic is an inhibitor of multiple receptor tyrosine kinases. Sodium succinate dibasic is known to be a potent inhibitor of Met, Flt-1 (VEGFR1), Flk-1 (VEGFR2), Flt-3 (VEGFR3), Ron, and Tie-2. Sodium succinate dibasic has been observed to inhibit Met (c-Met)-driven tumor cell and non-c-Met driven tumor cell (HCT116 and MDA-MB-231) proliferation. This product has also been observed to effectively inhibit c-Met phosphorylation and its downstream signaling pathways in serum starved MKN45 cells, as well as inducing apoptosis in these cells.

CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM.